Evidence map›Paper›PMID 34170189›Full record

ArticleNanomedicine (London, England)2021

2021: an immunotherapy odyssey and the rise of nucleic acid nanotechnology.

Martin Panigaj, Marina A Dobrovolskaia, Kirill A Afonin

Abstract readEditorial
In one paragraph

Article in Nanomedicine (London, England), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Martin PanigajInstitute of Biology & Ecology, Faculty of Science, Pavol Jozef Safarik University in Kosice, Kosice, 04154, Slovak Republic.ORCID 0000-0002-0940-8737
Marina A DobrovolskaiaNanotechnology Characterization Lab, Frederick National Laboratory for Cancer Research sponsored by The National Cancer Institute, Frederick, MD 21702, USA.ORCID 0000-0002-4233-9227
Kirill A AfoninDepartment of Chemistry, Nanoscale Science Program, University of North Carolina, Charlotte, NC 28223, USA.ORCID 0000-0002-6917-3183

Funding

WORK ORDER 126643 B539 EXPAND IC SUITE75N91019D00024 · NIAID · LEIDOS BIOMEDICAL RESEARCH, INC. · PI PENDLETON, RICHARD · 2019 to 2025
$3932.6M
SMART NANPs: new molecular platform for communication with human immune system and modulation of therapeutic responsesR35GM139587 · NIGMS · UNIVERSITY OF NORTH CAROLINA CHARLOTTE · PI AFONIN, KIRILL A · 2021 to 2025
$1.8M
Characterization of various multifunctional nucleic acid nanoparticles and understanding their immunotoxicityR01GM120487 · NIGMS · UNIVERSITY OF NORTH CAROLINA CHARLOTTE · PI AFONIN, KIRILL A · 2017 to 2020
$1.5M
NCI NIH HHS 75N91019D00024NIGMS NIH HHS R01 GM120487NIGMS NIH HHS R01GM120487, R35GM139587NIGMS NIH HHS R35 GM139587
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

NanoparticlesNeoplasmsNucleic AcidsDrug Delivery SystemsHumansImmunotherapyNanotechnologyNucleic Acidsdrug deliveryimmunotherapymRNA vaccinesnucleic acid nanoparticlestherapeutic nucleic acids

Identifiers

PMID34170189
PMCPMC8330809

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.